IP Library Granted Patent US 8,887,477
Granted Patent B2
US 8,887,477 · App. 12/619,118 · Granted Nov 18, 2014

E beam sterilization of medical devices comprising bioactive coating

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,887,477
App. No.
12/619,118
Granted
Nov 18, 2014
Kind
B2
Abstract

The invention provides a method for single-step terminal sterilization process for bio-active heparin coatings on materials and biomaterials containing heparin used in medical devices, such as catheters, tissue engineering scaffolds, or drug delivery carrier materials. This may include any medical device or implantable that could benefit from improved antithrombotic and biocompatible heparin surfaces. Other relevant device examples may include heparin or a heparin derivative coated stents to reduce clotting and restenosis, dental or ophthalmological implants. These materials may comprise additional polymeric compositions such as polyethyleneimine, dextran sulfate or their modified forms. These polymers together with heparin coatings may be applied to other substrate of medical devices such as metal, ceramics or biologically derived materials.

Claims (14)

1. A method of sterilizing a medical device having a heparin coating, wherein the heparin coating is applied to the medical device with a drug filling process, the method comprising the steps of:

placing the medical device in a package having a drying agent therein;

flushing the package with a non-reactive gas at least one time;

creating a vacuum within the package at least one time to remove any remaining gasses and moisture;

sealing the package; and

exposing the package and the medical device to one or more doses of electron beam radiation for a predetermined period of time and at a predetermined dose level and temperature, the one or more doses of electron beam radiation reversing the heparin activity loss during the drug filling process of the heparin coating.

2. The medical method of claim 1 , wherein the device is selected from the group consisting of cardiovascular, endovascular, and neurovascular stents, drug-eluting cardiovascular, endovascular, and neurovascular stents, endovascular graft, vascular and vein stent graft, angioplasty balloon, AV shunt, oxygenators, artificial heart membranes and assisting devices, AAA devices.

3. The method of claim 1 , wherein the medical device comprises a material selected from the group consisting of stainless steel, aluminum, nitinol, cobalt chromium, and titanium and the alloys of them.

4. The method of claim 1 , wherein the medical device additionally comprises a material selected from the group consisting of polyacetal, polyurethane, polyester, polytetrafluoroethylene, polyethylene, polymethylmethacrylate, polyhydroxyethyl methacrylate, polyvinyl alcohol, polypropylene, polymethylpentene, polyetherketone, polyphenylene oxide, polyvinyl chloride, polycarbonate, polysulfone, acrylonitrile-butadiene-styrene, polyetherimide, polyvinylidene fluoride, and copolymers and combinations thereof.

5. The method of claim 1 , wherein the medical device additionally comprises a material selected from the group consisting of polylactic acid, polyglycolic acid, poly(lactide-co-glycolide), polycaprolactone, polyparadioxanone, polytrimethylene carbonate and their copolymers, collagen, elastin, chitin, coral, hyaluronic acid, bone and combinations thereof.

6. The method of claim 1 , wherein the heparin is selected from the group consisting of unfractionated heparin, partially depolymerized heparin, low molecular weight heparin (LMWH), and other chemically or biologically modified heparin.

7. The method of claim 1 , wherein the E beam dose is between 10 KGy to 40 KGy.

8. The method of claim 1 , wherein the medical device additionally contains a pharmaceutically active component.

9. The method of claim 8 wherein the pharmaceutical agent is selected from an anti-proliferatives consisting of a rapamycin, a paclitaxel, and the derivatives and analogs.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 1, 2025
From: CARDINAL HEALTH SWITZERLAND 515 GMBH; CARDINAL HEALTH 529, LLC; CORDIS CORPORATION; FLEXIBLE STENTING SOLUTIONS, INC
To: CORDIS US CORP
Reel/Frame 072987/0675 →
SECURITY INTEREST Recorded Oct 1, 2025
From: CORDIS US CORP.; ACCESS CLOSURE, LLC
To: HPS INVESTMENT PARTNERS, LLC
Reel/Frame 072973/0157 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 31, 2017
From: CORDIS CORPORATION
To: CARDINAL HEALTH SWITZERLAND 515 GMBH
Reel/Frame 042126/0259 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 16, 2009
From: FALOTICO, ROBERT; LI, CHENGXUE; NGUYEN, THAI MINH; PARKER, THEODORE L.; ZHAO, JONATHON Z.
To: CORDIS CORPORATION
Reel/Frame 023522/0518 →